Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir. - Wikidata - wikimedia - TriplyDB

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.

http://www.wikidata.org/entity/Q35156156

about

ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection Role of genetic polymorphisms in hepatitis C virus chronic infection.Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study Recent advances in management of the HIV/HCV coinfected patient.Pharmacogenetics of ribavirin-induced anemia in hepatitis C.Pharmacogenetics of ribavirin-induced anemia in HCV patients.Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients.SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.

P2860

Q28606732-25DE725A-F9D4-4250-82A5-E13B777EA4A8 Q35779058-58DC4C3A-03FA-4FA4-B7C4-9E6E69AE9406 Q35799774-8268D7F8-0D55-4E9E-9AD5-D354B10DA791 Q35869247-3272FB35-7649-491F-AA5B-E44BEAD23A19 Q36575497-CF1E98B4-8A69-4619-9C85-82F22E45D08A Q40567799-BB8EBB39-4268-4CA9-883E-C84714482A29 Q40650428-48F2A4F6-012D-4B9C-9868-061AF12A7721 Q41143424-2DCBD7C6-1355-4F02-A16F-7920708FEAE3 Q41547430-4B9921C6-94B3-4147-BBE0-8401254BCBAA

P2860

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.

http://www.wikidata.org/entity/Q35156156

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Limited utility of ITPA defici ...... fibrosis receiving Telaprevir.

@ast

Limited utility of ITPA defici ...... fibrosis receiving Telaprevir.

@en

type

label

Limited utility of ITPA defici ...... fibrosis receiving Telaprevir.

@ast

Limited utility of ITPA defici ...... fibrosis receiving Telaprevir.

@en

prefLabel

Limited utility of ITPA defici ...... fibrosis receiving Telaprevir.

@ast

Limited utility of ITPA defici ...... fibrosis receiving Telaprevir.

@en

P1433

Q35156156-43122171-2432-4E7F-BE85-42E5B1855184

P1476

Q35156156-45A64645-333B-4507-B3F4-1E619482B19B

P2093

Q35156156-3F88DDE2-B92A-4CCD-9895-2DAA2A9CFA67

Q35156156-4752A0E1-640D-4F02-B83A-9A7C536387A5

Q35156156-5EE012AA-573C-404C-B29D-755284F9AEA2

Q35156156-6B25FD77-CEE0-4172-93A8-B18BF3609D1E

Q35156156-A0ED9D62-3740-4DC8-82BD-EE105426806F

Q35156156-EE3169A2-B809-42C7-953D-1BF874948F77

Q35156156-FE272340-21AE-4813-A718-C07A1E735D13

P2860

Q35156156-0DCD711C-113F-4AE1-AB84-01DFA0A4FBE9

Q35156156-0FED2E51-CE9C-4876-9732-63440BF05B91

Q35156156-1039CBC9-595C-44F2-847B-260C47DF5F3D

Q35156156-1A76ACF9-14E5-4B5D-B2C5-2411BF3CCFD5

Q35156156-1CC8B0D1-4764-4611-95F9-A6DEFD039EEF

Q35156156-208B0E9C-B3B6-4A89-85E2-C580EF060288

Q35156156-318449B9-FB51-4014-918F-0F47319B36E3

Q35156156-326525ED-5D07-4FDD-9110-6CD901C788AC

Q35156156-361709FE-C044-489C-B08F-D32A2D8B7C55

Q35156156-384718E1-7274-4A5A-82F7-9D990757C261

P304

Q35156156-4D8CB67B-92D7-4D4C-86A8-82CEB346B77F

P31

Q35156156-01666BFB-3057-49A9-9CA6-BCCF859ABEF2

P356

Q35156156-52EA5211-44FA-43DC-9490-F29154480B57

P407

Q35156156-0C6B5CB2-7E41-4099-8F60-FAEFF001835A

P433

Q35156156-7A88D473-E76E-4A37-91F2-3D6C51F09C10

P478

Q35156156-7532DB75-C1CF-45BD-96DA-566C5D87AA75

P50

Q35156156-B208D56A-154F-4047-B6D7-08A2B9F84A2B

Q35156156-DEF5C0A4-1DE3-408A-B44B-C640FBF0B33B

P577

Q35156156-74AE5FD3-AECB-4ED7-B5E9-1830E31ECFE1

P5875

Q35156156-4E35AAA7-C0B3-454C-863F-A3494507C709

P698

Q35156156-2EE7DC6A-C1E9-40F9-A8FA-BE4D6E90ACED

P932

Q35156156-9D9D043B-0227-4C7F-9C55-81C00B5ADB8F

P356

JOURNAL.PONE.0095881

P1433

P1476

Limited utility of ITPA defici ...... fibrosis receiving Telaprevir.

@en

P2093

Alessio Aghemo

http://www.w3.org/2001/XMLSchema#string

Davide Castaldi

http://www.w3.org/2001/XMLSchema#string

Eleonora Grassi

http://www.w3.org/2001/XMLSchema#string

Elisabetta Degasperi

http://www.w3.org/2001/XMLSchema#string

Enrico Galmozzi

http://www.w3.org/2001/XMLSchema#string

Massimo Colombo

http://www.w3.org/2001/XMLSchema#string

Roberta Soffredini

http://www.w3.org/2001/XMLSchema#string

P2860

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials.

Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations.

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.

P304

e95881

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0095881

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Roberta D'Ambrosio

Mariagrazia Rumi

P577

2014-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261838721

http://www.w3.org/2001/XMLSchema#string

P698

24760000

http://www.w3.org/2001/XMLSchema#string

P932

3997406

http://www.w3.org/2001/XMLSchema#string